FDA May Speed Drug Ad Review For Fee

Law360, New York (November 21, 2006, 12:00 AM EST) -- The U.S. Food and Drug Administration has reached a tentative agreement with pharmaceutical companies that would allow companies to pay the FDA fees to inspect their television ads in exchange for a speedier review.

Fees from the deal would help pay for the new staff needed to review the industry’s TV ads, the Wall Street Journal reported.

The FDA's Division of Drug Marketing, Advertising and Communications was recently restructured to address the ever-increasing workload of reviewing direct-to-consumer advertising materials.

In early September, the original DTC review...
To view the full article, register now.